FOLD:NSD-Amicus Therapeutics Inc. (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 9.92

Change

0.00 (0.00)%

Market Cap

USD 1.28B

Volume

5.79M

Analyst Target

USD 19.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Amicus Therapeutics Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of next-generation medicines for orphan diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.53 (+0.54%)

USD 120.95B
REGN Regeneron Pharmaceuticals Inc

-12.36 (-1.17%)

USD 115.81B
MRNA Moderna Inc

+1.12 (+0.97%)

USD 45.51B
ALNY Alnylam Pharmaceuticals Inc

+4.29 (+1.76%)

USD 30.78B
ARGX argenx NV ADR

+1.27 (+0.29%)

USD 26.20B
BNTX BioNTech SE

-0.07 (-0.09%)

USD 20.40B
GMAB Genmab AS

+0.05 (+0.20%)

USD 16.65B
RPRX Royalty Pharma Plc

-0.31 (-1.18%)

USD 15.75B
BGNE BeiGene Ltd

-0.96 (-0.66%)

USD 15.73B
BMRN Biomarin Pharmaceutical Inc

+0.09 (+0.11%)

USD 15.63B

ETFs Containing FOLD

GHII 5.50 % 0.44 %

N/A

N/A
DX2E:XETRA Xtrackers - S&P Global In.. 4.15 % 0.00 %

-0.02 (-0.20%)

USD 0.21B
XSGI:SW Xtrackers S&P Global Infr.. 4.15 % 0.00 %

-0.10 (-0.20%)

USD 0.22B
GRBIC 3.35 % 0.00 %

N/A

N/A
SBIO ALPS Medical Breakthrough.. 2.22 % 0.50 %

-1.00 (-0.20%)

USD 0.10B
XSGI:LSE Xtrackers S&P Global Infr.. 0.00 % 0.00 %

-11.50 (-0.20%)

USD 0.22B
XGID:LSE Xtrackers S&P Global Infr.. 0.00 % 0.00 %

+0.02 (+-0.20%)

USD 0.21B
DX2E:F Xtrackers - S&P Global In.. 0.00 % 0.00 %

-0.05 (-0.20%)

USD 0.21B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.09% 39% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.09% 39% F 22% F
Trailing 12 Months  
Capital Gain -21.02% 56% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.02% 56% F 35% F
Trailing 5 Years  
Capital Gain -19.02% 69% C- 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.02% 69% C- 38% F
Average Annual (5 Year Horizon)  
Capital Gain 11.28% 68% D+ 70% C-
Dividend Return 11.28% 68% D+ 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.60% 63% D 39% F
Risk Adjusted Return 25.29% 81% B- 60% D-
Market Capitalization 1.28B 92% A 84% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 19.70 7% 5%
Price / Cash Flow Ratio -42.53 98% 93%
Price/Free Cash Flow Ratio -35.99 97% 93%
Management Effectiveness  
Return on Equity -126.10% 34% 17%
Return on Invested Capital -14.11% 82% 37%
Return on Assets -5.08% 93% 41%
Debt to Equity Ratio 242.15% 8% 9%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.